Skip to main content
Figure 1 | Journal for ImmunoTherapy of Cancer

Figure 1

From: Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Figure 1

Schematic diagrams of lentiviral vectors for 3C10-CAR and miR-17-92. (A) The 3C10-CAR-expressing vector pELNS-3C10-CAR. The EF1α promoter drives the CAR construct containing the 3C10 scFv for targeting of EGFRvIII. The CAR also incorporates CD28 as well as 4-1BB and CD3ζ domains. (B) The miR-17-92-expressing lentiviral vector FG12-EF1a-miR-17/92. miR-17-92 is expressed under the control of the EF1a promoter. The vector also contains the human UbiC promoter driving the EGFP as a marker gene for transduced cells. Abbreviations: RSV/HIV-1 5’LTR = Hybrid RSV promoter-R/U5 long terminal repeat; EF1α = Human elongation factor 1α-subunit promoter; VH = Variable region in the heavy chain of the 3C10 immunoglobulin; VL = Variable region in the light chain of the 3C10 immunoglobulin; HIV-1 Δ-3′LTR = Self-inactivating 3′ long terminal repeat with deletion in U3 region; CMV/HIV-1 5′LTR = Hybrid CMV promoter-R/U5 long terminal repeat; UbiC = Ubiquitin C promoter.

Back to article page